New Jersey is currently home to 1701 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
NCT06807632
Recruiting
This study will test whether valemetostat in combination with atezolizumab is a safe treatment that causes few or mild side effects in people with extensive-stage small cell lung cancer (SCLC). The researchers will test different doses of valemetostat to find the highest dose that causes few or mild side effects in participants. After the dose is found, researchers will test it in a new group of participants to learn more about the safety of the study treatment and see if it is an effective trea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Extensive-stage Small-cell Lung Cancer
Register for Updates
A Study of Sotorasib in People With Brain Tumors
NCT06807619
Recruiting
The researchers are doing this study to find out how effective sotorasib is at getting into KRAS G12C+ brain tumors. The researchers will also find out whether sotorasib is a safe and effective treatment for people undergoing surgical resection of KRAS G12C+ metastatic brain tumors, and do tests that show how the body absorbs, distributes, and gets rid of sotorasib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey
Conditions: Brain Tumor
Register for Updates
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06634589
Recruiting
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study will initially include two substudies, and more substudies may be added as they become available.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Summit Medical Group, Florham Park, New Jersey
Conditions: B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
Register for Updates
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386
Recruiting
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Local Institution - 0346, Paterson, New Jersey
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections
NCT06369220
Recruiting
This study is designed to assess the comparative clinical utility of the point of care cobas® liat CT/NG/MG to current standard practices in the diagnosis and treatment of urogenital infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Planned Parenthood of Northern, Central, and Southern New Jersey, Inc., Hamilton Square, New Jersey
Conditions: Chlamydia Trachomatis Infection, Neisseria Gonorrhoeae Infection, Mycoplasma Genitalium Infection
Register for Updates
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT06161584
Recruiting
A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Gender:
ALL
Ages:
60 years and above
Trial Updated:
01/28/2025
Locations: Mid Atlantic Retina Research (01-014), Cherry Hill, New Jersey
Conditions: Geographic Atrophy
Register for Updates
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
NCT05904496
Recruiting
This is a First in Human (FIH) Phase 1, multicenter, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-30813 as monotherapy or in combination with tislelizumab in participants with advanced or metastatic solid tumors. The study will be conducted in 2 parts: Phase 1a dose escalation and Phase 1b dose expansion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Advanced Solid Tumors
Register for Updates
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases
NCT05869955
Recruiting
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Atlantic Health System Overlook Medical Center, Summit, New Jersey
Conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis
Register for Updates
A Clinical Trial of Combination HIV-Specific Broadly Neutralizing Monoclonal Antibodies Combined With ART Initiation During Acute HIV Infection to Induce HIV Remission
NCT05719441
Recruiting
A5388 is a phase II, two-arm, randomized, double-blind, placebo-controlled study that will enroll 48 antiretroviral therapy (ART)-naïve adults with acute HIV infection (AHI) in order to determine whether: * Administration of combination HIV-specific broadly neutralizing antibody (bNAb) therapy in addition to ART during acute HIV infection (AHI) will be safe. * Participants who receive combination bNAb therapy in addition to ART during AHI will be more likely to demonstrate a delay in time to HI... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/28/2025
Locations: 31786, New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey
Conditions: Acute HIV Infection
Register for Updates
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
NCT05710328
Recruiting
This phase II trial tests how well an imaging procedure called fludeoxyglucose F-18 (FDG) positron emission tomography/computed tomography (PET/CT) works in predicting response to standard of care chemotherapy prior to surgery in patients with HER2-positive stage IIa-IIIc breast cancer. FDG is a radioactive tracer that is given in a vein before PET/CT imaging and helps to identify areas of active cancer. PET and CT are imaging techniques that make detailed, computerized pictures of areas inside... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Cooper Hospital University Medical Center, Camden, New Jersey
Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
Register for Updates
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Gender:
ALL
Ages:
All
Trial Updated:
01/28/2025
Locations: Jersey Shore University Medical Center, Neptune, New Jersey
Conditions: H3 K27M, Glioma
Register for Updates
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133
Recruiting
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/28/2025
Locations: Research Site, Newark, New Jersey
Conditions: Lupus Nephritis
Register for Updates